Navigation Links
Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
Date:1/28/2010

r of additional data presentations and publications supporting both the clinical and economic benefits of this therapy to occur during the year. We also have a program in place to generate activity at existing centers and from referring cardiologists, and will continue our successful efforts to add new centers and help centers achieve DT reimbursement certification. We will also increase our investments in key technology initiatives, which include the ongoing introduction of the new HeartMate peripherals, enhancements to the HeartMate II platform, the development of a miniaturized pump based on the HeartMate II platform and our development program for the HeartMate III," Burbach said.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues for 2009 of $373.9 million versus revenues of $313.6 million in 2008.  Cardiovascular Division revenues in fiscal 2009 were $280.0 million versus $215.0 million a year ago. Revenues at the company's International Technidyne Corporation (ITC) division were $94.0 million versus $98.6 million a year ago.

The company provided a breakdown of sales by product for 2009 versus 2008. The HeartMate product line accounted for $229.8 million in revenues, a 43 percent increase over sales of $160.8 million a year ago. The Thoratec product line, which includes the PVAD and IVAD, accounted for sales of $34.8 million, a 16 percent decline versus sales of $41.7 million a year ago.  CentriMag sales in 2009 were $12.6 million, a 28 percent increase over sales of $9.9 million a year ago. The balance of Cardiovascular Division revenues reflects contrib
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... SAN JOSE, Calif. , Aug. 21, 2014 /PRNewswire/ ... a medical device company that pioneered the use of ... surgical (MIS) device indicated for fusion of the sacroiliac ... ) published an update to its Lumbar Fusion ... MIS SI joint fusion procedure.  The policy states that ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... candidate, has been granted orphan drug designation from the ... of pediatric Clostridium difficile infection (CDI).  This ... covers all formulations of fidaxomicin used to treat ...
... 2011 ULURU Inc. (NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... 5,000,000 shares of its common stock at a price per ... an institutional investor, resulting in gross proceeds of approximately $500,000. ...
Cached Medicine Technology:Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4ULURU Inc. to Raise $500,000 in Registered Direct Offering 2
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 Seattle, WA chiropractors Dr. ... Eastlake Chiropractic and Massage Center have recently welcomed ... Rina Lang, LMP and Mike Larios, LMP have ... massage techniques, and have developed their expertise working in ... particularly important in a clinical environment where massage is ...
(Date:8/21/2014)... August 21, 2014 The results of ... in The Journal of the American Medical Association (JAMA) ... cancers and reduces unnecessary recalls. Memorial Healthcare System was ... study. , “This study confirms what we already know ... cancers we want to find and, at the same ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... The Swedish-American Life Science Summit, (SALSS) ... on the Future of Medicine and the challenges ... , With the mission to turn new sciences ... business and science. "Over the years SALSS has ... diverse community with representatives challenging the boundaries of ...
Breaking Medicine News(10 mins):Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... , , , ... DST Health Solutions, a leading provider of software and services ... certification, a designation demonstrating its commitment to quality product development. ... Registrar, an independent auditing firm, for meeting the guidelines set ...
... LEBANON, Tenn., July 28 Health Connect Partners, Inc. ( ... the title sponsor of its 2009 Fall Hospital Pharmacy Conference. ... up to 200 directors of pharmacy from some of the largest ... sessions led by healthcare industry experts, the Hospital Pharmacy Conference will ...
... COLORADO SPRINGS, Colo., July 28 Now that summer is in ... across the county. , , With millions enjoying their ... for home pool and hot tub safety is urgent. , , ... home pool and hot tub owners to make safety their priority by following ...
... , WILTON, Conn., July 28, ... Friday, July 24 and Saturday, July 25 in Chicago, Eucerin was ... incidental sun exposure and give them a glimpse into their skin,s ... year marked Eucerin,s first appearance at the annual BlogHer Conference, connecting ...
... , CHICAGO, July 28 When at the pool ... the harmful rays of the sun. But do we remember to apply sunscreen to ... on the feet from unprotected sun exposure, and overlook applying sunscreen to the area. ... of the foot is prevalent and can even be fatal if not caught early. ...
... Mylan Inc. (Nasdaq: MYL ) today reported that in ... proactively and as a courtesy had contacted the U.S. Food and ... a recent news article. As a result, the FDA visited the ... the baseless accusations in the article were unfounded. The FDA noted ...
Cached Medicine News:Health News:DST Health Solutions Achieves ISO 9001:2008 Certification 2Health News:Cardinal Health Announced as Title Sponsor of the Health Connect Partners' 2009 Fall Hospital Pharmacy Conference 2Health News:Seven Tips for Safer Home Swimming Pools and Hot Tubs 2Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Sunscreen on Your Feet? Doctors Urge Sunscreen Use and Exams to Prevent Skin Cancer on Feet 2Health News:Mylan Reports That the FDA Determined That All Accusations Were Unfounded 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: